Thymosin Beta-4 Research: What 1,406 Studies Show (2026) | RetatrutideCompare

Thymosin Beta-4 — 1,406 studies indexed on PubMed. Sequesters G-actin (1:1 stoichiometry), regulating cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, anti-inflammation. Half-life: ~12 hours. FDA status: Investigational.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Thymosin Beta-4?

There are approximately 1,406 studies indexed on PubMed that mention Thymosin Beta-4 (TB-4, Tβ4), based on a search last updated 2026-06-18.

Is Thymosin Beta-4 FDA-approved?

FDA status: Investigational.

How does Thymosin Beta-4 work?

Sequesters G-actin (1:1 stoichiometry), regulating cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, anti-inflammation.

Sequesters G-actin (1:1 stoichiometry), regulating cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, anti-inflammation.

Reference facts

Also known as
TB-4, Tβ4
Category
Healing & Tissue Repair
Mechanism of action
Sequesters G-actin (1:1 stoichiometry), regulating cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, anti-inflammation.
Targets
G-actin, Multiple cytokine pathways
Indications under research or approved
Dry eye disease (RGN-259 Phase 3), Cardiac repair, wound healing (clinical trials)
Regulatory status (reference entry)
Investigational
Half-life
~12 hours
Sequence
SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Sequence notes
43-residue ubiquitous actin-sequestering peptide; N-terminal acetylated in vivo.
Molecular weight (Da)
4963
PDB accession
1HJ0
Originator / sponsor
RegeneRx Biopharmaceuticals (RGN-259)
First reported
1981

Primary References

Explore research articles about Thymosin Beta-4

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.